These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17923463)

  • 1. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
    Conen D; Everett BM; Glynn RJ; Ridker PM
    Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
    Weisser B; Vetter H; Mengden T
    Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
    Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
    Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
    Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia.
    Rosenson RS; Wolff D; Tangney CC
    Clin Sci (Lond); 2004 Feb; 106(2):215-7. PubMed ID: 12967321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
    Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
    Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome.
    Suliman ME; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2006 Jun; 21(6):1603-10. PubMed ID: 16476720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
    Tardif JC; Curnew GP; Leclerc JM; Rehel B
    Can J Clin Pharmacol; 2008; 15(2):e177-87. PubMed ID: 18515919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
    Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
    Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual activity in hypertensive men.
    Della Chiesa A; Pfiffner D; Meier B; Hess OM
    J Hum Hypertens; 2003 Aug; 17(8):515-21. PubMed ID: 12874608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
    Schühlen H; Abts M; Kastrati D
    Herz; 2007 Aug; 32(5):419-25. PubMed ID: 17687532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
    Ridker PM; Danielson E; Rifai N; Glynn RJ;
    Hypertension; 2006 Jul; 48(1):73-9. PubMed ID: 16714425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.